FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155792409> ?p ?o ?g. }

• W2155792409 endingPage "258" @default.
• W2155792409 startingPage "254" @default.
• W2155792409 abstract "ABSTRACT S/GSK1349572 is a novel integrase inhibitor with potent in vitro anti-HIV activity, an in vitro resistance profile different from those of other integrase inhibitors, and favorable preclinical safety and pharmacokinetics (PK). Randomized, double-blind, placebo-controlled single-dose and multiple-dose, dose escalation studies evaluated the PK, safety, and tolerability of S/GSK1349572 for healthy subjects. In the single-dose study, two cohorts of 10 subjects each (8 active, 2 receiving placebo) received suspension doses of 2, 5, 10, 25, 50, and 100 mg in an alternating panel design. In the multiple-dose study, three cohorts of 10 subjects each (8 active, 2 receiving placebo) received suspension doses of 10, 25, and 50 mg once daily for 10 days. A cytochrome P450 3A (CYP3A) substudy with midazolam was conducted with the 25-mg dose. Laboratory testing, vital signs, electrocardiograms (ECGs), and PK sampling were performed at regular intervals. S/GSK1349572 was well tolerated. Most adverse events (AEs) were mild, with a few moderate AEs reported. Headache was the most common AE. No clinically significant laboratory trends or ECG changes were noted. PK was linear over the dosage range studied. The steady-state geometric mean area under the concentration-time curve over a dosing interval (AUC 0-τ ) and maximum concentration of the drug in plasma ( C max ) ranged from 16.7 μg·h/ml (coefficient of variation [CV], 15%) and 1.5 μg/ml (CV, 24%) at a 10-mg dose to 76.8 μg·h/ml (CV, 19%) and 6.2 μg/ml (CV, 15%) at a 50-mg dose, respectively. The geometric mean steady-state concentration at the end of the dosing interval ( C τ ) with a 50-mg dose was 1.6 μg/ml, approximately 25-fold higher than the protein-adjusted 90% inhibitory concentration (0.064 μg/ml). The half-life was approximately 15 h. S/GSK1349572 had no impact on midazolam exposure, indicating that it does not modulate CYP3A activity. The PK profile suggests that once-daily, low milligram doses will achieve therapeutic concentrations." @default.
• W2155792409 created "2016-06-24" @default.
• W2155792409 creator A5041385302 @default.
• W2155792409 creator A5043729176 @default.
• W2155792409 creator A5048162351 @default.
• W2155792409 creator A5058472962 @default.
• W2155792409 creator A5063738784 @default.
• W2155792409 creator A5064337611 @default.
• W2155792409 creator A5074341326 @default.
• W2155792409 date "2010-01-01" @default.
• W2155792409 modified "2023-10-03" @default.
• W2155792409 title "Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers" @default.
• W2155792409 cites W2007831756 @default.
• W2155792409 cites W2024158612 @default.
• W2155792409 cites W2053125329 @default.
• W2155792409 cites W2087400133 @default.
• W2155792409 cites W2109360985 @default.
• W2155792409 cites W2150504993 @default.
• W2155792409 doi "https://doi.org/10.1128/aac.00842-09" @default.
• W2155792409 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2798521" @default.
• W2155792409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19884365" @default.
• W2155792409 hasPublicationYear "2010" @default.
• W2155792409 type Work @default.
• W2155792409 sameAs 2155792409 @default.
• W2155792409 citedByCount "207" @default.
• W2155792409 countsByYear W21557924092012 @default.
• W2155792409 countsByYear W21557924092013 @default.
• W2155792409 countsByYear W21557924092014 @default.
• W2155792409 countsByYear W21557924092015 @default.
• W2155792409 countsByYear W21557924092016 @default.
• W2155792409 countsByYear W21557924092017 @default.
• W2155792409 countsByYear W21557924092018 @default.
• W2155792409 countsByYear W21557924092019 @default.
• W2155792409 countsByYear W21557924092020 @default.
• W2155792409 countsByYear W21557924092021 @default.
• W2155792409 countsByYear W21557924092022 @default.
• W2155792409 countsByYear W21557924092023 @default.
• W2155792409 crossrefType "journal-article" @default.
• W2155792409 hasAuthorship W2155792409A5041385302 @default.
• W2155792409 hasAuthorship W2155792409A5043729176 @default.
• W2155792409 hasAuthorship W2155792409A5048162351 @default.
• W2155792409 hasAuthorship W2155792409A5058472962 @default.
• W2155792409 hasAuthorship W2155792409A5063738784 @default.
• W2155792409 hasAuthorship W2155792409A5064337611 @default.
• W2155792409 hasAuthorship W2155792409A5074341326 @default.
• W2155792409 hasBestOaLocation W21557924092 @default.
• W2155792409 hasConcept C111113717 @default.
• W2155792409 hasConcept C112705442 @default.
• W2155792409 hasConcept C126322002 @default.
• W2155792409 hasConcept C142462285 @default.
• W2155792409 hasConcept C142724271 @default.
• W2155792409 hasConcept C197934379 @default.
• W2155792409 hasConcept C203014093 @default.
• W2155792409 hasConcept C204787440 @default.
• W2155792409 hasConcept C22979827 @default.
• W2155792409 hasConcept C27081682 @default.
• W2155792409 hasConcept C2777068322 @default.
• W2155792409 hasConcept C2777288759 @default.
• W2155792409 hasConcept C2777302000 @default.
• W2155792409 hasConcept C2778335254 @default.
• W2155792409 hasConcept C2778375690 @default.
• W2155792409 hasConcept C2993143319 @default.
• W2155792409 hasConcept C3013748606 @default.
• W2155792409 hasConcept C71924100 @default.
• W2155792409 hasConcept C76318530 @default.
• W2155792409 hasConcept C98274493 @default.
• W2155792409 hasConceptScore W2155792409C111113717 @default.
• W2155792409 hasConceptScore W2155792409C112705442 @default.
• W2155792409 hasConceptScore W2155792409C126322002 @default.
• W2155792409 hasConceptScore W2155792409C142462285 @default.
• W2155792409 hasConceptScore W2155792409C142724271 @default.
• W2155792409 hasConceptScore W2155792409C197934379 @default.
• W2155792409 hasConceptScore W2155792409C203014093 @default.
• W2155792409 hasConceptScore W2155792409C204787440 @default.
• W2155792409 hasConceptScore W2155792409C22979827 @default.
• W2155792409 hasConceptScore W2155792409C27081682 @default.
• W2155792409 hasConceptScore W2155792409C2777068322 @default.
• W2155792409 hasConceptScore W2155792409C2777288759 @default.
• W2155792409 hasConceptScore W2155792409C2777302000 @default.
• W2155792409 hasConceptScore W2155792409C2778335254 @default.
• W2155792409 hasConceptScore W2155792409C2778375690 @default.
• W2155792409 hasConceptScore W2155792409C2993143319 @default.
• W2155792409 hasConceptScore W2155792409C3013748606 @default.
• W2155792409 hasConceptScore W2155792409C71924100 @default.
• W2155792409 hasConceptScore W2155792409C76318530 @default.
• W2155792409 hasConceptScore W2155792409C98274493 @default.
• W2155792409 hasIssue "1" @default.
• W2155792409 hasLocation W21557924091 @default.
• W2155792409 hasLocation W21557924092 @default.
• W2155792409 hasLocation W21557924093 @default.
• W2155792409 hasLocation W21557924094 @default.
• W2155792409 hasOpenAccess W2155792409 @default.
• W2155792409 hasPrimaryLocation W21557924091 @default.
• W2155792409 hasRelatedWork W1822154343 @default.
• W2155792409 hasRelatedWork W1990533335 @default.
• W2155792409 hasRelatedWork W2091460425 @default.
• W2155792409 hasRelatedWork W2155792409 @default.
• W2155792409 hasRelatedWork W2479254611 @default.

• next